The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Study examines the effect of TP53 mutations on outcomes in MDS patients receiving haploidentical haematopoietic stem cell ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.

On January 8, 2025, the Department of Veterans Affairs (VA) announced it was adding eight (8) new presumptives for disabled veterans. These new presumptives are: acute and chronic ...

Under the direction of Dr. Guru Subramanian Guru Murthy at the Medical College of Wisconsin Cancer Center, the trial ( NCT06502145) will evaluate the safety, tolerability, and recommended Phase II ...

Myelodysplastic syndromes (MDS) are marked by ineffective hematopoiesis and dysplasia, which elevate the risk of progression to acute myeloid leukemia (AML). The inflammatory environment in MDS alters ...

Shares were up 30% to 5.18 Canadian dollars Wednesday. Medexus will target a commercial launch in the first half of calendar 2025. The company believes product-level revenue in the U.S. has the ...

The PACT Act of 2022 extended eligibility for VA health care to veterans with toxic exposures, including veterans from the Vietnam, Gulf War, and Post-9/11 eras.